ATE114458T1 - Bioelastomeres arzneimittelabgabesystem. - Google Patents

Bioelastomeres arzneimittelabgabesystem.

Info

Publication number
ATE114458T1
ATE114458T1 AT91302648T AT91302648T ATE114458T1 AT E114458 T1 ATE114458 T1 AT E114458T1 AT 91302648 T AT91302648 T AT 91302648T AT 91302648 T AT91302648 T AT 91302648T AT E114458 T1 ATE114458 T1 AT E114458T1
Authority
AT
Austria
Prior art keywords
polymer
physiological condition
functional group
composition
group
Prior art date
Application number
AT91302648T
Other languages
English (en)
Inventor
Dan W Urry
Original Assignee
Bioelastics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelastics Res Ltd filed Critical Bioelastics Res Ltd
Application granted granted Critical
Publication of ATE114458T1 publication Critical patent/ATE114458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2045—Polyamides; Polyaminoacids, e.g. polylysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91302648T 1990-03-27 1991-03-26 Bioelastomeres arzneimittelabgabesystem. ATE114458T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49969790A 1990-03-27 1990-03-27

Publications (1)

Publication Number Publication Date
ATE114458T1 true ATE114458T1 (de) 1994-12-15

Family

ID=23986317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91302648T ATE114458T1 (de) 1990-03-27 1991-03-26 Bioelastomeres arzneimittelabgabesystem.

Country Status (6)

Country Link
US (1) US6328996B1 (de)
EP (1) EP0449592B1 (de)
JP (1) JPH0729942B2 (de)
AT (1) ATE114458T1 (de)
DE (1) DE69105323T2 (de)
ES (1) ES2067150T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727639B2 (en) * 1996-11-27 2000-12-21 Gunther Beisel Composition for producing a long-lasting satiation effect
GB9718463D0 (en) * 1997-08-29 1997-11-05 Dynal As Biomolecules
WO1999043271A1 (en) * 1998-02-27 1999-09-02 Bioelastics Research, Ltd. Injectable implants for tissue augmentation and restoration
AU3867400A (en) * 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
EP1434571B1 (de) * 2001-10-05 2005-05-11 SurModics, Inc. Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
EP1478305A2 (de) * 2002-02-07 2004-11-24 Rutgers, The State University Therapeutische polyester und polyamide
GB0412631D0 (en) * 2004-06-07 2004-07-07 Cambridge Applied Polymers Ltd Polymer release system
AU2005295472B2 (en) * 2004-10-14 2011-11-10 Trustees Of Tufts College Electrochemically degradable polymers
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US20070009602A1 (en) * 2005-06-24 2007-01-11 Setton Lori A Direct drug delivery system based on thermally responsive biopolymers
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) * 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US20090098110A1 (en) * 2007-05-30 2009-04-16 Duke University Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
EP2464370B1 (de) 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modifizierte vasoaktive darmpeptide
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP3139949B1 (de) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Zusammensetzungen enthaltend ein vip-elp fusionsprotein zur verwendung in der behandlung von mukoviszidose
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
JP6600405B2 (ja) * 2016-04-07 2019-10-30 インダストリー−ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 新血管生成抑制のための血管内皮成長因子受容体ターゲッティングペプチド−エラスチン融合ポリペプチド及び自己組立ナノ構造体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867520A (en) * 1971-04-14 1975-02-18 Ajinomoto Kk Medicated polyamino acid film for occlusive dressing therapy
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
FR2353282A1 (fr) * 1976-06-02 1977-12-30 Invap Etablissement Application de l'elastine et de ses derives en cosmetique
US4187852A (en) * 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
DE3104815C2 (de) * 1980-02-13 1983-07-07 Japan Atomic Energy Research Institute, Tokyo Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4605413A (en) 1983-09-19 1986-08-12 The University Of Alabama At Birmingham Stimulation of chemotaxis by chemotactic peptides
US4589882A (en) * 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4693718A (en) * 1985-10-31 1987-09-15 University Of Alabama In Birmingham Stimulation of chemotaxis by chemotactic peptides
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
ES2054052T3 (es) * 1988-06-30 1994-08-01 Centre Nat Rech Scient Procedimiento de preparacion de sistemas coloidales dispersables de una proteina en forma de nanoparticulas.

Also Published As

Publication number Publication date
JPH04221323A (ja) 1992-08-11
JPH0729942B2 (ja) 1995-04-05
EP0449592B1 (de) 1994-11-30
DE69105323D1 (de) 1995-01-12
DE69105323T2 (de) 1995-06-01
US6328996B1 (en) 2001-12-11
EP0449592A1 (de) 1991-10-02
ES2067150T3 (es) 1995-03-16

Similar Documents

Publication Publication Date Title
ATE114458T1 (de) Bioelastomeres arzneimittelabgabesystem.
ATE122879T1 (de) Verabreichungsformen für pharmaka.
NO912769D0 (no) Avleveringssystem for medikamenter.
ATE434423T1 (de) Medikamentenfreisetzender stent
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
EP1234586A3 (de) Selektiv auf der Leber wierkenden Pharmaka
NO872381D0 (no) Fremgangsmaate for fremstilling av langsomt frigivende preparater.
NO884474D0 (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE3884314D1 (de) Polymermischung mit umkehrphasen Morphologie zur kontrollierten Wirkstoffabgabe.
DE3783257D1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
ATE69952T1 (de) Theophyllintablette mit verzoegerter freigabe.
IL115138A (en) Implantable polymer-containing molded articles for the administration of active substances to plants and processes for the preparation thereof
ATE54824T1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
SE9202208D0 (sv) Vaevnadsfoerstaerkning
JPS6456055A (en) Medical molded article composed of lactic acid/epsilon-caprolactone copolymer and its preparation
NO983917D0 (no) Anvendelse av IL-7 for behandling av autoimmune sykdommer og særlig insulinavhengig diabetes mellitus
Noble Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility.
DE69123344D1 (de) Künstliches blutgefäss sowie herstellung desselben
ATE96025T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
Soheir Experimental trials in treatment of chronic Salmonellosis and carrier state with bilharzial infection
Larsen et al. TSS: The Mystery Unfolds.
Rozkin et al. Comparative study of the anticoagulant activity of sulfated polysaccharides from marine brown algae
Frick Prophylactic use of antibiotics against postoperative infections in reconstructive vascular surgery with alloplastic material.
SE8204283L (sv) Polypeptid-mellanprodukt for framstellning av en polypeptid-slutprodukt och dess farmaceutiskt acceptabla salter med biologisk formaga att inducera utveckling av t-lymfocyter men inte av komplementreceptor (cr?72+) b...

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties